Eisai Inc. and Helsinn Group May 28 said that the Food and Drug Administration has approved Aloxi (palonosetron hydrochloride) injection for preventing acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy in children ages 1 month to less than 17 years.
This is the first approval of a product for acute chemotherapy-induced nausea and vomiting in patients ages 1 month to 6 months, the company said. The age of peak cancer incidence among children occurs within the first year of life, so this approval offers an important option to children and infants undergoing chemotherapy.
Aloxi ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.